School of Medicine


Showing 21-39 of 39 Results

  • Suzanne Pfeffer

    Suzanne Pfeffer

    Emma Pfeiffer Merner Professor of Medical Sciences

    Current Research and Scholarly InterestsThe major focus of our research is to understand the molecular basis of inherited Parkinson's Disease (PD). We focus on the LRRK2 kinase that is inappropriately activated in PD and how it phosphorylates Rab GTPases, blocking the formation of primary cilia in specific regions of the brain. The absence of primary cilia renders cells unable to carry out Hedgehog signaling that is critical for neuroprotective pathways that sustain dopamine neurons.

  • Harlan Pinto

    Harlan Pinto

    Associate Professor of Medicine (Oncology), Emeritus

    Current Research and Scholarly InterestsClinical Interests: general oncology, head and neck cancer Research Interests: chemoprevention trials and combined modality approaches to head and neck cancer

  • Sharon Pitteri

    Sharon Pitteri

    Associate Professor (Research) of Radiology (Diagnostic Sciences Laboratory)

    Current Research and Scholarly InterestsThe Pitteri laboratory is focused on the discovery and validation of proteins that can be used as molecular indicators of risk, diagnosis, progression, and recurrence of cancer. Proteomic technologies, predominantly mass spectrometry, are used to identify proteins in the blood that are differentially regulated and/or post-translationally modified with disease state. Using human plasma samples, tumor tissue, cancer cell lines, and genetically engineered mouse models, the origins of these proteins are being investigated. A major goal of this research is to define novel molecular signatures for breast and ovarian cancers, including particular sub-types of these diseases. This laboratory is also focused on the identification of proteins with expression restricted to the surface of cancer cells which can be used as novel targets for molecular imaging technologies.

  • Philip A. Pizzo, M.D.

    Philip A. Pizzo, M.D.

    David and Susan Heckerman Professor, Emeritus

    BioPhilip Pizzo, MD, is the David and Susan Heckerman Professor Emeritus. Pizzo served as Dean of the Stanford School of Medicine from April 2001 to December 1, 2012. He was Founding Director of the Stanford Distinguished Careers Institute from 2012 - 2022. Pizzo began rabbinical studies at the Academy for Jewish Religion, California in 2022 and studies in Spiritual Care and Counseling at the Jewish Theological Seminary in 2024.

    Dr. Pizzo career focused on the diagnosis, management, prevention and treatment of childhood cancers and the infectious complications that occur in children whose immune systems are compromised by cancer and AIDS. He has been a leader in academic medicine and in longevity and the future of higher education.
    Pizzo received his MD degree with Honors and Distinction in Research from the University of Rochester in 1970 and completed an internship and residency at the Boston Children’s Hospital. He was a fellow in pediatric oncology at the National Cancer Institute (NCI) and served as head of the NCI’s infectious disease section, chief of pediatric oncology, and scientific director for the Division of Clinical Sciences between. Before joining Stanford in 2001, he was the physician-in-chief of Boston Children’s Hospital and Chair of the Department of Pediatrics at Harvard Medical School, where he was also the Thomas Morgan Rotch Professor of Pediatrics.

    Dr. Pizzo is the author of more than 650 scientific articles and 16 books and monographs. He also served as Editor-in-Chief of Current Opinion in Pediatrics from 2012 - 2019. He co-led the National Academy of Medicine 2011 report Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research; and “Dying in America: Improving Quality and Honoring Individual Preferences at the End of Life” that was published in 2015.

    Pizzo has received numerous awards and honors, including the Public Health Service Outstanding Service Medal in 1995, the Barbara Bohen Pfiefer Award for Scientific Excellence in 1991, the Elizabeth Kubler-Ross Award in 2008, the Ronald McDonald Charities “Award of Excellence” in 2009, and the John and Emma Bonica Public Service Award in 2013. He is the 2012 recipient of the John Howland Award, the highest honor for lifetime achievement bestowed by the American Pediatric Society. In 2019 he received the John Stearns Medal from the New York Academy of Medicine. Pizzo received the 2021 International Immunocompromised Host Society’s Lifetime Distinguished Career Award. He received the Dean’s Medal from the University of Rochester in 2023.

    Pizzo has been elected to the Association of American Physicians, the American Society of Clinical Investigation, the American Pediatric Society, the National Academy of Medicine. He has served as Chair of the Association of Academic Health Centers and Chair of the Council of Deans of the Association of American Medical Colleges. He was elected to the Board of Directors of the American Society for Clinical Oncology and the Infectious Diseases Society of America. He was President of the International Immunocompromised Host Society between1998 – 2011, and he served on the Governing Board for the California Institute of Regenerative Medicine from 2004 - 2012. Pizzo was elected to the Board of Trustees of the University of Rochester from 2009 - 2022 and the Board of Overseers of Koc University in Istanbul, Turkey from 2010 - 2022. He served Academic Advisory Council for Merritt Hawkins between 2015 - 2022., and the Advisory Board to the Milken Institute Center on Aging from 2015 - 2022. He was elected to the Board of Directors of the Ludwig Institute for Cancer Research from 2012- 2022. In 2015 Pizzo was elected to the Board of Directors of Global Blood Therapeutics through 2023, and in 2019 he was elected to the Board of Directors of Hillel at Stanford through 2023.

  • Sylvia K. Plevritis, PhD

    Sylvia K. Plevritis, PhD

    William M. Hume Professor in the School of Medicine, Professor of Biomedical Data Science and of Radiology

    Current Research and Scholarly InterestsMy research program focuses on computational modeling of cancer biology and cancer outcomes. My laboratory develops stochastic models of the natural history of cancer based on clinical research data. We estimate population-level outcomes under differing screening and treatment interventions. We also analyze genomic and proteomic cancer data in order to identify molecular networks that are perturbed in cancer initiation and progression and relate these perturbations to patient outcomes.

  • Jonathan Pollack

    Jonathan Pollack

    Professor of Pathology
    On Leave from 02/01/2025 To 05/31/2025

    Current Research and Scholarly InterestsResearch in the Pollack lab centers on translational genomics, with a focus on prostate diseases. The lab employs next-generation sequencing, single-cell and spatial genomics, gene editing, and human cell/tissue-based modeling to uncover disease mechanisms, biomarkers and therapeutic targets. Current areas of emphasis include benign prostatic hyperplasia, prostate cancer, and rare/neglected cancer types (ameloblastoma, liposarcoma).

  • Matthew Porteus

    Matthew Porteus

    Sutardja Chuk Professor of Definitive and Curative Medicine

    BioDr. Porteus was raised in California and was a local graduate of Gunn High School before completing A.B. degree in “History and Science” at Harvard University where he graduated Magna Cum Laude and wrote an thesis entitled “Safe or Dangerous Chimeras: The recombinant DNA controversy as a conflict between differing socially constructed interpretations of recombinant DNA technology.” He then returned to the area and completed his combined MD, PhD at Stanford Medical School with his PhD focused on understanding the molecular basis of mammalian forebrain development with his PhD thesis entitled “Isolation and Characterization of TES-1/DLX-2: A Novel Homeobox Gene Expressed During Mammalian Forebrain Development.” After completion of his dual degree program, he was an intern and resident in Pediatrics at Boston Children’s Hospital and then completed his Pediatric Hematology/Oncology fellowship in the combined Boston Chidlren’s Hospital/Dana Farber Cancer Institute program. For his fellowship and post-doctoral research he worked with Dr. David Baltimore at MIT and CalTech where he began his studies in developing homologous recombination as a strategy to correct disease causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. Following his training with Dr. Baltimore, he took an independent faculty position at UT Southwestern in the Departments of Pediatrics and Biochemistry before again returning to Stanford in 2010 as an Associate Professor. During this time his work has been the first to demonstrate that gene correction could be achieved in human cells at frequencies that were high enough to potentially cure patients and is considered one of the pioneers and founders of the field of genome editing—a field that now encompasses thousands of labs and several new companies throughout the world. His research program continues to focus on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand diseases that affect children including infant leukemias and genetic diseases that affect the muscle. Clinically, Dr. Porteus attends at the Lucille Packard Children’s Hospital where he takes care of pediatric patients undergoing hematopoietic stem cell transplantation.

  • George A. Poultsides, MD, MS

    George A. Poultsides, MD, MS

    Professor of Surgery (General Surgery)

    Current Research and Scholarly InterestsClinical trials of experimental diagnostics and therapeutics; outcomes analysis following combined modality treatment of hepatic, pancreatic, and gastrointestinal malignancies.

  • Guillem Pratx

    Guillem Pratx

    Associate Professor of Radiation Oncology (Radiation Physics)

    Current Research and Scholarly InterestsThe Physical Oncology Lab is interested in making a lasting impact on translational cancer research by building novel physical tools and methods.

  • Judith Prochaska

    Judith Prochaska

    Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)

    Current Research and Scholarly InterestsDr. Prochaska's research expertise centers on technology-mediated health behavior change interventions including targets of tobacco, physical activity, and dietary change. Working with Alaska Native and Latino communities, people with serious mental illness, alcohol and drug problems, or heart disease, and jobseekers and the unhoused, Dr. Prochaska’s research combines stage-tailored interventions with pharmacotherapy and utilizes interactive expert system interventions and social media.

  • Carla Pugh, MD, PhD

    Carla Pugh, MD, PhD

    Thomas Krummel Professor

    Current Research and Scholarly InterestsThe Technology Enabled Clinical Improvement (T.E.C.I.) Center is a multidisciplinary team of researchers dedicated to the design and implementation of advanced engineering technologies that facilitate data acquisition relating to clinical performance.

  • Silvina Pugliese, MD

    Silvina Pugliese, MD

    Clinical Associate Professor, Dermatology

    BioSilvina Pugliese, M.D., is a Clinical Assistant Professor of Dermatology and Attending Physician at the Stanford Medicine Outpatient Center and Stanford Cancer Institute. She attended medical school at Boston University and completed her residency at Loma Linda, serving as Chief Resident in her final year. Dr. Pugliese practices Supportive Dermato-Oncology (SDO) at the Stanford main campus and also launched the South Bay Cancer Center's SDO Clinic in 2015. She is interested in the management of cutaneous complications associated with chemotherapy, radiation therapy, organ transplantation, and their impact on patient quality of life.